About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

Kidswell Bio Corporation(4584) Summary

4584
TSE Growth
Kidswell Bio Corporation
109
JPY
-7
(-6.03%)
Apr 4, 3:30 pm JST
0.74
USD
Apr 4, 2:30 am EDT
Result
PTS
outside of trading hours
107
Apr 4, 9:18 pm JST
Summary Chart Historical News Financial Result
PER
PBR
4.83
Yield
ー%
Margin Trading Ratio
Stock Price
Apr 4, 2025
Opening Apr 4, 9:00 am
116 JPY 0.79 USD
Previous Close Apr 3
116 JPY 0.78 USD
High Apr 4, 9:00 am
116 JPY 0.79 USD
Low Apr 4, 1:09 pm
104 JPY 0.71 USD
Volume
3,294,700
Trading Value
0.36B JPY 2.48M USD
VWAP
109.93 JPY 0.75 USD
Minimum Trading Value
10,900 JPY 74 USD
Market Cap
4.68B JPY 0.03B USD
Number of Trades
864
Liquidity & Number of Trades
As of Apr 4, 2025
Liquidity
Mid
1-Year Average
299
1-Year High Aug 27, 2024
6,400
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 28, 2025 0 3,959,700
Mar 21, 2025 0 4,026,000
Mar 14, 2025 0 3,695,400
Mar 7, 2025 0 3,628,400
Feb 28, 2025 200 3,469,100 17345.50
Company Profile
Kidswell Bio Corporation is a drug discovery venture originating from Hokkaido University. The company focuses on biopharmaceuticals, biosimilars, antibody drugs, and pediatric medicines.
Sector
Pharmaceuticals
Kidswell Bio Corporation, a drug discovery venture born out of Hokkaido University, initially operated in three business areas: biopharmaceuticals, biosimilars, and cell therapy (regenerative medicine). However, to maximize corporate value and achieve rapid stock price recovery and growth, the company has shifted its strategy to concentrate management resources on the biosimilar business, which provides a stable revenue base, and the cell therapy business, which serves as a growth foundation. In the biosimilar business, the company has been involved in the development of four products, establishing a stable revenue base through sales of launched products. In the cell therapy business, Kidswell Bio is advancing the development of regenerative medicine products utilizing stem cells from deciduous tooth dental pulp (SHED). The company is responsible for manufacturing process development and active pharmaceutical ingredient supply in the biosimilar business, and covers from basic research to manufacturing in the cell therapy business. Both business segments emphasize partnerships with pharmaceutical companies, and the company is actively working to expand its operations.